TRANSDERMAL SOLID LIPID NANOPARTICLES OF CLOMIPHENE CITRATE FOR ENHANCED PCOS TREATMENT
DOI:
https://doi.org/10.22159/ijap.2026v18i1.55917Keywords:
Nanoparticles, Clomiphene citrate, Box–behnken design, Optimizing SLN, Particle size, Transdermal drug delivery systemAbstract
Objective: To develop and evaluate a novel dissolving microneedle patch containing clomiphene citrate‑loaded solid lipid nanoparticles (CC‑SLNs), aiming to enable sustained transdermal drug delivery for PCOS treatment, enhance therapeutic effectiveness, and reduce side effects linked to oral administration.
Methods: CC‑SLNs were formulated using hot homogenization and ultra-sonication and optimized via a box–behnken design targeting ideal particle size, entrapment efficiency, drug loading, and zeta potential. Microneedle patches were fabricated from biocompatible polymers (polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol 400), featuring ~915 µm-high needles for effective dermal penetration. In vitro characterization assessed patch thickness, folding endurance (~300 folds), moisture uptake, and drug release kinetics. Ex vivo release studies were performed on human skin models. For in vivo evaluation, female wistar rats were randomly assigned to control (saline), oral CC, or CC‑SLN microneedle patch groups (n = 6 each). Skin irritation (erythema and edema) was monitored at 1, 24, 48, and 72 h post-application, and at 72 h, blood samples were collected for LH, FSH, and insulin resistance evaluation. Skin biopsies were obtained for histopathological analysis.
Results: SLN components were selected based on Particle size (242±11 nm), Zetapotential (25.6±0.9 mv) and PDI (0.24±0.02). Regression analysis was performed using design experts which displays the significance of p-value. Optimized batch was selected by point prediction and Batch No. 17 was selected. SEM study confirmed uniform and structurally. In vitro and ex vivo release studies demonstrated sustained drug release (~89% over 5 days in vitro; ~78% ex vivo). In vivo, the CCSLN patch delivered prolonged systemic activity, minimized hormonal fluctuations, and showed significantly reduced skin irritation and histopathological changes compared to oral administration.
Conclusion: The developed CC‑SLN microneedle patch represents a promising transdermal approach for PCOS management. It delivers clomiphene citrate in a controlled and sustained manner, enhances treatment efficacy, and offers superior safety and tolerability relative to conventional oral therapy, based on pharmacodynamics, hormonal profiles, and dermal safety in a rat model.
References
1. Patel N, Shaker IA, Patel K. Harnessing the power of G-protein coupled receptor-120 in redefining insulin resistance and inflammation management in polycystic ovary syndrome. AJPCR. 2025;18(6):143-6. doi: 10.22159/ajpcr.2025v18i6.54774.
2. Monisha MM, Prakash M. Targeting polycystic ovarian syndrome inflammation: docking and phytochemical profiling of anti-inflammatory compounds in leonotis nepetifolia. AJPCR. 2025;18(6):168-75. doi: 10.22159/ajpcr.2025v18i6.54487.
3. Bhatt F, Patel D. Fabrication and screening of solid lipid nanoparticles-loaded microneedle patch for polycystic ovary syndrome treatment. AJPCR. 2025;18(7):109-14. doi: 10.22159/ajpcr.2025v18i7.54740.
4. Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28(2):409-21. doi: 10.1016/S0889-8529(05)70077-3, PMID 10352926.
5. Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. J Clin Endocrinol Metab. 2012;97(10):E1871-9. doi: 10.1210/jc.2012-1350, PMID 22837188.
6. Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261-71. doi: 10.4103/jhrs.JHRS_95_18, PMID 33627974.
7. Yilmaz EG, Ece E, Erdem O, ES I, Inci F. A sustainable solution to skin diseases: ecofriendly transdermal patches. Pharmaceutics. 2023;15(2):579. doi: 10.3390/pharmaceutics15020579, PMID 36839902.
8. Guillot AJ, Martinez Navarrete M, Garrigues TM, Melero A. Skin drug delivery using lipid vesicles: a starting guideline for their development. J Control Release. 2023;355:624-54. doi: 10.1016/j.jconrel.2023.02.006, PMID 36775245.
9. Guillot AJ, Jornet Molla E, Landsberg N, Milian Guimera C, Montesinos MC, Garrigues TM. Cyanocobalamin ultraflexible lipid vesicles: characterization and in vitro evaluation of drug-skin depth profiles. Pharmaceutics. 2021;13(3):418. doi: 10.3390/pharmaceutics13030418, PMID 33804652.
10. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization and in vitro release study of albendazole encapsulated nanosize liposomes. Int J Nanomedicine. 2010;5:101-8. doi: 10.2147/ijn.s8030, PMID 20309396.
11. Keller S, Heerklotz H, Jahnke N, Blume A. Thermodynamics of lipid membrane solubilization by sodium dodecyl sulfate. Biophys J. 2006;90(12):4509-21. doi: 10.1529/biophysj.105.077867, PMID 16581838.
12. Hernandez Borrell J, Pons M, Juarez JC, Estelrich J. The action of triton X-100 and sodium dodecyl sulphate on lipid layers effect on monolayers and liposomes. J Microencapsul. 1990;7(2):255-9. doi: 10.3109/02652049009021838, PMID 2329450.
13. Igarashi T, Shoji Y, Katayama K. Anomalous solubilization behavior of dimyristoylphosphatidylcholine liposomes induced by sodium dodecyl sulfate micelles. Anal Sci. 2012;28(4):345-50. doi: 10.2116/analsci.28.345, PMID 22498460.
14. Permana AD, Tekko IA, McCrudden MT, Anjani QK, Ramadon D, McCarthy HO. Solid lipid nanoparticle-based dissolving microneedles: a promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. J Control Release. 2019;316:34-52. doi: 10.1016/j.jconrel.2019.10.004, PMID 31655132.
15. Todo H. Transdermal permeation of drugs in various animal species. Pharmaceutics. 2017;9(3):33. doi: 10.3390/pharmaceutics9030033, PMID 28878145.
16. Ng SF, Rouse JJ, Sanderson FD, Meidan V, Eccleston GM. Validation of a static franz diffusion cell system for in vitro permeation studies. AAPS PharmSciTech. 2010;11(3):1432-41. doi: 10.1208/s12249-010-9522-9, PMID 20842539.
17. Carreras JJ, Tapia Ramirez WE, Sala A, Guillot AJ, Garrigues TM, Melero A. Ultraflexible lipid vesicles allow topical absorption of cyclosporin a. Drug Deliv Transl Res. 2020;10(2):486-97. doi: 10.1007/s13346-019-00693-4, PMID 31811620.
18. Miranda M, Cardoso C, Vitorino C. Fast screening methods for the analysis of topical drug products. Processes. 2020;8(4):397. doi: 10.3390/pr8040397.
19. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.
20. Ahad A, Al Saleh AA, Al Mohizea AM, Al Jenoobi FI, Raish M, Yassin AE. Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017;25(7):1040-6. doi: 10.1016/j.jsps.2017.01.006, PMID 29158713.
21. Ahad A, Al Saleh AA, Al Mohizea AM, Al Jenoobi FI, Raish M, Yassin AE. Formulation and characterization of phospholipon 90 G and tween 80-based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. 2018;23(8):787-93. doi: 10.1080/10837450.2017.1330345, PMID 28504046.
22. Gbian DL, Omri A. Lipid-based drug delivery systems for disease management. Biomedicines. 2022;10(9):2137. doi: 10.3390/biomedicines10092137, PMID 36140237.
23. Teodorescu M, Bercea M, Morariu S. Biomaterials of PVA and PVP in medical and pharmaceutical applications: perspectives and challenges. Biotechnol Adv. 2019;37(1):109-31. doi: 10.1016/j.biotechadv.2018.11.008, PMID 30472307.
24. Dawud H, Abu Ammar A. Rapidly dissolving microneedles for the delivery of steroid-loaded nanoparticles intended for the treatment of inflammatory skin diseases. Pharmaceutics. 2023;15(2):526. doi: 10.3390/pharmaceutics15020526, PMID 36839849.
25. Ritger PL, Peppas NA. A simple equation for description of solute release I. fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres cylinders or discs. J Control Release. 1987;5(1):23-36. doi: 10.1016/0168-3659(87)90034-4.
26. Chourasia MK, Kang L, Chan SY. Nanosized ethosomes bearing ketoprofen for improved transdermal delivery. Results Pharm Sci. 2011;1(1):60-7. doi: 10.1016/j.rinphs.2011.10.002, PMID 25755983.
27. Zhang YT, Shen LN, Wu ZH, Zhao JH, Feng NP. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy. Int J Pharm. 2014;471(1-2):449-52. doi: 10.1016/j.ijpharm.2014.06.001, PMID 24907596.
28. Miranda M, Volmer Z, Cornick A, Goody A, Cardoso C, Pais AA. In vitro studies into establishing therapeutic bioequivalence of complex topical products: weight of evidence. Int J Pharm. 2024;656:124012. doi: 10.1016/j.ijpharm.2024.124012, PMID 38537923.
29. Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Arch Gynecol Obstet. 2006;274(4):187-97. doi: 10.1007/s00404-006-0171-x, PMID 16685527.
30. Jiang D. TCM treatment of polycystic ovary and PCOS. JCMAH. 2017;2(1):555-78. doi: 10.19080/JCMAH.2017.02.555578.
31. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-45. doi: 10.1111/j.1365-2265.2006.02587.x, PMID 16886951.
32. Motta AB. The role of obesity in the development of polycystic ovary syndrome. Curr Pharm Des. 2012;18(17):2482-91. doi: 10.2174/13816128112092482, PMID 22376149.
33. Dahan MH, Reaven G. Relationship among obesity, insulin resistance and hyperinsulinemia in the polycystic ovary syndrome. Endocrine. 2019;64(3):685-9. doi: 10.1007/s12020-019-01899-9, PMID 30900204.
34. Isikoglu M, Berkkanoglu M, Cemal H, Ozgur K. Polycystic ovary syndrome: what is the role of obesity. In: Polycystic ovary syndrome. Kent, UK: Anshan Publishing, Limited; 2007. p. 157-63.
35. Peigne M, Dewailly D. Long-term complications of polycystic ovary syndrome (PCOS). Ann Endocrinol (Paris). 2014;75(4):194-9. doi: 10.1016/j.ando.2014.07.111, PMID 25156132.
36. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745-63. doi: 10.2147/IJWH.S70314, PMID 26261426.
37. Mukherjee P, Sanyal S, Chadha S, Mukherjee S. The impact of polycystic ovary syndrome (PCOS) on the risk of developing ovarian cancer and thyroid disorders: a comprehensive review. Endocr Metab Immune Disord Drug Targets. 2024;24(5):562-72. doi: 10.2174/0118715303266512231103075551, PMID 37986267.
38. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1):1-17. doi: 10.1046/j.1365-2265.2003.01842.x, PMID 14678281.
39. Liao B, Qiao J, Pang Y. Central regulation of PCOS: abnormal neuronal-reproductive metabolic circuits in PCOS pathophysiology. Front Endocrinol (Lausanne). 2021;12:667422. doi: 10.3389/fendo.2021.667422, PMID 34122341.
40. Baoying Liao, Jie Qiao, Yanli Pang. Central regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Sec. Neuroendocrine Science; 2021. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2021.667422/full.
41. Walters KA, Moreno Asso A, Stepto NK, Pankhurst MW, Rodriguez Paris VR, Rodgers RJ. Key signalling pathways underlying the aetiology of polycystic ovary syndrome. J Endocrinol. 2022;255(1):R1-26. doi: 10.1530/JOE-22-0059, PMID 35980384.
42. Bao SH, Sheng SL, Peng YF, Lin QD. Effects of letrozole and clomiphene citrate on the expression of HOXA10 and integrin αvβ3 in uterine epithelium of rats. Fertil Steril. 2009;91(1):244-8. doi: 10.1016/j.fertnstert.2007.11.024, PMID 18249394.
43. Omran E, El Sharkawy M, El Mazny A, Hammam M, Ramadan W, Latif D. Effect of clomiphene citrate on uterine hemodynamics in women with unexplained infertility. Int J Womens Health. 2018;10:147-52. doi: 10.2147/IJWH.S155335, PMID 29670406.
44. Mehdinejadiani S, Amidi F, Mehdizadeh M, Barati M, Pazhohan A, Alyasin A. Effects of letrozole and clomiphene citrate on Wnt signaling pathway in endometrium of polycystic ovarian syndrome and healthy women. Biol Reprod. 2019;100(3):641-8. doi: 10.1093/biolre/ioy187, PMID 30184105.
45. Salam EA, Essam ME, ElSawy NA. Effect of clomiphene citrate on the ovary of adult rat. Jokull. 2015;65(12):26-44.
46. Barnes LE, Meyer RK. Effects of ethamoxytriphetol MRL-37 and clomiphene on reproduction in rats. Fertil Steril. 1962;13(5):472-80. doi: 10.1016/S0015-0282(16)34632-5, PMID 13865101.
47. Gadalla MA, Huang S, Wang R, Norman RJ, Abdullah SA, El Saman AM. Effect of clomiphene citrate on endometrial thickness, ovulation pregnancy and live birth in anovulatory women: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;51(1):64-76. doi: 10.1002/uog.18933, PMID 29055102.
48. Tavaniotou A, Albano C, Smitz J, Devroey P. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril. 2002;77(4):733-7. doi: 10.1016/S0015-0282(01)03265-4, PMID 11937125.
49. Mac Dougall MJ, Tan SL, Hall V, Balen A, Mason BA, Jacobs HS. Comparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective randomized trial. Fertil Steril. 1994;61(6):1052-7. doi: 10.1016/S0015-0282(16)56755-7, PMID 8194616.
50. Ochin H, Ma X, Wang L, Li X, Song J, Meng Y. Low dose clomiphene citrate as a mild stimulation protocol in women with unsuspected poor in vitro fertilization result can generate more oocytes with optimal cumulative pregnancy rate. J Ovarian Res. 2018;11(1):37. doi: 10.1186/s13048-018-0408-x, PMID 29728130.
51. Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertil Steril. 2000;73(3):587-90. doi: 10.1016/S0015-0282(99)00584-1, PMID 10689017.
52. Al Inany H, Azab H, El Khayat W, Nada A, El Khattan E, Abou Setta AM. The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertil Steril. 2010;94(6):2167-71. doi: 10.1016/j.fertnstert.2010.01.069, PMID 20236631.
53. EL Sherry TM, Derar D, Ali Hussein HA, Shahin AY, Fahmy S. Effect of clomiphene citrate on follicular recruitment development and superovulation during the first follicular wave in rahmani ewes. Int J Endocrinol Metab. 2012;9(3):403-8. doi: 10.5812/Kowsar.1726913X.2381.
54. Bukhari SA, Ali S, Zubair M, Ahmad I, Rehman UU. Effect of clomiphene citrate and human chorionic gonadotropin (hCG) on ovulation induction in prepubertal Sahiwal heifers. Asian Pac J Reprod. 2016;5(3):232-5. doi: 10.1016/j.apjr.2016.04.010.
55. Mulabagal V, Annaji M, Kurapati S, Dash RP, Srinivas NR, Tiwari AK. Stability-indicating HPLC method for acyclovir and lidocaine in topical formulations. Biomed Chromatogr. 2020;34(3):e4751. doi: 10.1002/bmc.4751, PMID 31756271.
56. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62(11):1607-21. doi: 10.1111/j.2042-7158.2010.01030.x, PMID 21039545.
57. Shelley H, Babu RJ. Role of cyclodextrins in nanoparticle-based drug delivery systems. J Pharm Sci. 2018;107(7):1741-53. doi: 10.1016/j.xphs.2018.03.021, PMID 29625157.
Published
How to Cite
Issue
Section
Copyright (c) 2026 FORAM BHATT, DIPTI PATEL
This work is licensed under a Creative Commons Attribution 4.0 International License.